Skip to playerSkip to main content
  • 1 minute ago
An investigation into whether big pharmaceutical companies are meeting their commitments to biodiversity conservation, focusing on the Cali Fund's aims and the reality of contributions.

Category

🗞
News
Transcript
00:00But you have to ask yourself who are the real stakeholders here and who are the real game
00:05players. And it's not like unelected officials and it's not elected officials really either.
00:09It's actually much more likely to be private pharmaceutical companies. Like those are actually
00:15the people that COP talks and these sorts of commitments are trying to affect. So like in
00:222025, for example, they set up the Cali Fund. They launched the Cali Fund to encourage private
00:28companies that benefit from the kind of genetic biodiversity of nature to contribute to a fund
00:33to conservation. And it suggested that these companies make a voluntary contribution of 1%
00:39of their profits or 0.1% of their revenue. And it was trying to raise $1 billion annually.
00:45But at the start of COP17 on Monday, the fund had received just $7,085 and just about $10,000
00:55dollars or just above $10,000 in commitments. So these are major pharmaceutical companies
01:01that are benefiting from the biodiversity of nature and from the kind of genetic resources
01:06of the earth that we have. They are the ones that COP talks are targeting and they are the
01:11ones that are ignoring that call.
Comments

Recommended